The FDA, in a stark reversal, on Friday said it would reconsider its decision to remove Eli Lilly’s tirzepatide, from its ...

The FDA has decided to reconsider its previous decision that barred drug compounders from selling their versions of Eli Lilly ...

The FDA has agreed to revisit its decision to prevent compounders from selling versions of Eli Lilly's diabetes and weight ...

Federal regulators shook up a rapidly growing pharmaceutical marketplace when they announced that tirzepatide, the active ingredient in Eli Lilly’s Mounjaro and Zepbound, was no longer in shortage ...

The U.S. Food and Drug Administration on Friday agreed to reconsider a decision it made last month to bar drug compounders ...

In recent years, the pharmaceutical manufacturer has seen dizzying growth in its pipeline for a wide range of diseases. And ...

Senator Elizabeth Warren told the Federal Trade Commission that the acquisition of contract manufacturer Catalent could ...

Peptide companies' are creating knock-off versions of these drugs that have not been approved by the FDA and contain ...

Lilly has earmarked $200 million for the upgrade, a company spokesperson confirmed to Fierce Pharma. The new project will ...

PBMs are putting weight loss drugs, including Wegovy and Zepbound, on their national formularies, but coverage by plans is ...

Teva Pharmaceutical Industries will pay $450 to settle the Department of Justice's investigation into allegations of price fixing and misuse of funds for kickbacks. Other pharmaceutical news reports ...

There’s a war brewing over blockbuster weight loss medications — and patients are now getting caught in the crossfire.